Swiss National Bank’s Lifecore Biomedical LFCR Stock Holding History

Swiss National Bank’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-64,600	Closed	-$596K	–	2741
2021 Q3	$596K	Hold	64,600	–	–	﹤0.01%	2561
2021 Q2	$727K	Buy	64,600 +4,700	+8%	+$54.2K	﹤0.01%	2570
2021 Q1	$635K	Hold	59,900	–	–	﹤0.01%	2436
2020 Q4	$650K	Hold	59,900	–	–	﹤0.01%	2424
2020 Q3	$582K	Hold	59,900	–	–	﹤0.01%	2328
2020 Q2	$477K	Buy	59,900 +9,700	+19%	+$100K	﹤0.01%	2387
2020 Q1	$436K	Hold	50,200	–	–	﹤0.01%	2237
2019 Q4	$568K	Buy	50,200 +1,400	+3%	+$14.9K	﹤0.01%	2387
2019 Q3	$530K	Hold	48,800	–	–	﹤0.01%	2344
2019 Q2	$457K	Buy	48,800 +3,400	+7%	+$34.3K	﹤0.01%	2438
2019 Q1	$558K	Hold	45,400	–	–	﹤0.01%	2338
2018 Q4	$538K	Hold	45,400	–	–	﹤0.01%	2336
2018 Q3	$654K	Hold	45,400	–	–	﹤0.01%	2343
2018 Q2	$676K	Hold	45,400	–	–	﹤0.01%	2356
2018 Q1	$592K	Buy	45,400 +5,100	+13%	+$67K	﹤0.01%	2322
2017 Q4	$508K	Hold	40,300	–	–	﹤0.01%	2407
2017 Q3	$522K	Hold	40,300	–	–	﹤0.01%	2364
2017 Q2	$598K	Hold	40,300	–	–	﹤0.01%	2352
2017 Q1	$484K	Hold	40,300	–	–	﹤0.01%	2387
2016 Q4	$556K	Buy	40,300 +4,600	+13%	+$63.7K	﹤0.01%	2343
2016 Q3	$479K	Hold	35,700	–	–	﹤0.01%	2369
2016 Q2	$384K	Hold	35,700	–	–	﹤0.01%	2463
2016 Q1	$360K	Buy	35,700 +7,400	+26%	+$81.3K	﹤0.01%	2436
2015 Q4	$335K	Hold	28,300	–	–	﹤0.01%	2450
2015 Q3	$330K	Buy	28,300 +4,100	+17%	+$54.3K	﹤0.01%	2364
2015 Q2	$349K	Hold	24,200	–	–	﹤0.01%	2400
2015 Q1	$338K	Hold	24,200	–	–	﹤0.01%	2357
2014 Q4	$334K	Hold	24,200	–	–	﹤0.01%	2363
2014 Q3	$296K	Hold	24,200	–	–	﹤0.01%	2336
2014 Q2	$302K	Buy	24,200 +2,800	+13%	+$33K	﹤0.01%	2387
2014 Q1	$239K	Buy	21,400 +3,600	+20%	+$39.5K	﹤0.01%	2398
2013 Q4	$216K	Sell	17,800 -11,000	-38%	-$131K	﹤0.01%	2375
2013 Q3	$351K	Hold	28,800	–	–	﹤0.01%	2148
2013 Q2	$380K	Buy	+28,800	New	+$398K	﹤0.01%	2094

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Swiss National Bank's LFCR Position: Q4 2021 in Review

Swiss National Bank sold out of Lifecore Biomedical (LFCR) in Q4 2021, closing a stake of 64,600 shares — an estimated $596K sold.

Swiss National Bank first reported a position in LFCR in Q2 2013 and held it in 34 quarters. The position peaked at $727K in Q2 2021. 98 funds tracked by Wall St. Rank hold LFCR as of Q4 2021.

Swiss National Bank reported no remaining Lifecore Biomedical position as of Q4 2021 after selling out during the quarter.
Swiss National Bank sold 64,600 Lifecore Biomedical shares in Q4 2021, an estimated $596K.
Swiss National Bank first reported a position in Lifecore Biomedical in Q2 2013 and held it in 34 quarters.
Swiss National Bank's Lifecore Biomedical position peaked at $727K in Q2 2021.
98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2021.

Based on Swiss National Bank's 13F filing for Q4 2021, filed 8 Feb 2022.